

Journal of Zhejiang University SCIENCE B  
 ISSN 1673-1581 (Print); ISSN 1862-1783 (Online)  
 www.zju.edu.cn/jzus; www.springerlink.com  
 E-mail: jzus@zju.edu.cn



## Receptor-mediated gene delivery using polyethylenimine (PEI) coupled with polypeptides targeting FGF receptors on cells surface\*

LI Da<sup>1</sup>, WANG Qing-qing<sup>1</sup>, TANG Gu-ping<sup>2</sup>, HUANG Hong-liang<sup>1</sup>,  
 SHEN Fen-ping<sup>1</sup>, LI Jing-zhong<sup>1</sup>, YU Hai<sup>†‡1</sup>

<sup>(1)</sup>Institute of Immunology, Zhejiang University, Hangzhou 310058, China)

<sup>(2)</sup>Institute of Chemical Biology and Pharmaceutical Chemistry, Zhejiang University, Hangzhou 310028, China)

<sup>†</sup>E-mail: yuhai@zju.edu.cn

Received Feb. 21, 2006; revision accepted Apr. 21, 2006

**Abstract:** Objective: To construct a novel kind of nonviral gene delivery vector based on polyethylenimine (PEI) conjugated with polypeptides derived from ligand FGF with high transfection efficiency and according to tumor targeting ability. Methods: The synthetic polypeptides CR16 for binding FGF receptors was conjugated to PEI and the characters of the polypeptides including DNA condensing and particle size were determined. Enhanced efficiency and the targeting specificity of the synthesized vector were investigated in vitro and in vivo. Results: The polypeptides were successfully coupled to PEI. The new vectors PEI-CR16 could efficiently condense pDNA into particles with around 200 nm diameter. The PEI-CR16/pDNA polyplexes showed significantly greater transgene activity than PEI/pDNA in FGF receptors positive tumor cells in vitro and in vivo gene transfer, while no difference was observed in FGF receptors negative tumor cells. The enhanced transfection efficiency of PEI-CR16 could be blocked by excess free polypeptides. Conclusion: The synthesized vector could improve the efficiency of gene transfer and targeting specificity in FGF receptors positive cells. The vector had good prospect for use in cancer gene therapy.

**Key words:** FGF receptors, Polyethylenimine, Targeting, Gene delivery, Gene therapy

**doi:**10.1631/jzus.2006.B0906

**Document code:** A

**CLC number:** R730.54

### INTRODUCTION

At present, the choice of gene delivery vectors is the bottleneck in gene therapy (El-Aneed, 2004). Great concern on the safety and immunogenicity of viral vectors make nonviral vectors more attractive. Among kinds of nonviral vectors, polyethylenimine (PEI) has shown high transfection efficiency both in vitro and in vivo and attracted great attention (Boussif *et al.*, 1995; Neu *et al.*, 2005). But compared with viral vectors, PEI shows lower gene delivery efficiency, higher toxicity and lack of tumor cells targeting ability.

There are several strategies to modify PEI such

as PEGylation, link to ligands and so on (Wagner, 2004; Read *et al.*, 2005a). Among these strategies, linking ligands which bind specific receptor on cell membrane to PEI appear most attractive. Ligand-receptor mediated gene delivery enhances the targeting ability and transfection efficiency of PEI/pDNA polyplexes. There are researches on the linkage of ligands such as EGF, NGF, mannose, galactose, transferrin, folate, monoclonal antibody, etc. (Wagner, 2004). But to our knowledge, there is little attention on the linkage of FGF onto PEI.

In this study, the FGF receptor-targeting polypeptide CR16 (CYRSRKYTSWYVALKR) was linked to the sequence of FGF molecules (Plotnikov *et al.*, 2000) onto PEI to form PEI-CR16 polymer. Chemical characterization, gene transfection efficiency and the tumor targeting ability of PEI-CR16 polymers in vitro and in vivo were investigated.

<sup>‡</sup> Corresponding author

\* Project (Nos. 2001AA217071 and 2003AA216041) supported by the Hi-Tech Research and Development Program (863) of China

## MATERIALS AND METHODS

### Materials

Polyethylenimine (PEI, 25 kDa), SPDP ((N-Succinimidyl-3-(2-pyridyldithio))pro-pionate), DMF and DMSO were obtained from Sigma-Aldrich (St. Louis, MO, USA). The polypeptides CR16 (CYRSRKYTSWYVALKR,  $MW=2080$ ) were synthesized by GL Biochem (Shanghai) Ltd. Plasmid pCAG-Luc encoding luciferase was bought from Promega. HepG2 (FGF receptors positive), a human hepatocellular carcinoma cell line and PC-3 (FGF receptors negative), a human prostate adenocarcinoma cell line, were obtained from American Type Culture Collection ATCC (Rockville, MD). Female BALB/C athymic nude mice (4~6 weeks old) were purchased from Shanghai Slac Laboratory Animal Co. Ltd. (Shanghai, China).

### Synthesis of PEI-CR16

PEI (4.5 mg/ml, 5.6 ml) was reacted with SPDP (1.25 mg) in a mixture of NS and DMSO at room temperature for 1 h under the protection of nitrogen in the dark. When the reaction was finished, CR16 (1.56 mg) was mixed with the product of the first reaction at room temperature for 4 h under the protection of nitrogen gas. The product was dialyzed with the dialysis membrane (MW cutoff 10000) for 24 h and lyophilized for 48 h. The product was preserved at  $-20^{\circ}\text{C}$ .

### $^1\text{H}$ nuclear magnetic resonance ( $^1\text{H}$ NMR) assay

Five milligrams of the product was subjected to 8 scans  $^1\text{H}$  NMR analysis with Bruker 400 MHz NMR spectrometer at room temperature.

### Fourier transformed infrared spectroscopy (FT-IR) assay

FT-IR spectra were examined on an FT-IR spectrometer (Spectrum 2000, PERKIN ELMER).

### Cell viability assay

HepG2 and PC-3 cells were grown in DMEM supplemented with 10% FCS at  $37^{\circ}\text{C}$ , 5%  $\text{CO}_2$  in 96-well plates (Falcon, Becton Dickison, USA) at an initial density of 5000 cells/well; 24 h later, the growth medium was replaced by 200  $\mu\text{l}$  serum-free DMEM containing PEI or PEI-CR16 with different

concentrations (0, 1, 2, 4, 5, 10, 20, 50 and 100  $\mu\text{g}/\text{ml}$ ). After 36 h incubation, the cells viability was measured by MTT assay. The relative cell growth (%) of control cells cultured in media without PEI or PEI-CR16 was calculated by  $([A]_{\text{test}}/[A]_{\text{control}}) \times 100$ .

### Agarose gel electrophoresis assay

Varying amounts of polymers were mixed with 0.2  $\mu\text{g}$  of pDNA in 5% glucose solution. Gel electrophoresis was carried out at room temperature in TAE buffer in 1% (w/w) agarose gel at 100 V for 30 min. pDNA bands were visualized by a UV illuminator.

### Particle size test

Polyplexes of PEI/pDNA and PEI-CR16/pDNA were prepared at DNA concentration of 0.333  $\mu\text{g}/\text{ml}$ , N/P ratio was 5, 10, 20 and 30, respectively for samples. Sizes were measured with 90 Plus Particle Size Analyzer (Brookhaven Instruments Corporation, USA) at  $25^{\circ}\text{C}$  temperature. Scattering light was detected at  $90^{\circ}$  angle.

### In vitro gene transfer

HepG2 cells were cultured in 48-well plates (Falcon, Becton Dickison, USA) at a density of  $2.5 \times 10^4$ /well with 0.8 ml DMEM containing 10% FCS. Twenty-four hours later, the culture medium was replaced with 0.8 ml serum-free DMEM and the polyplexes of PEI/pCAG-Luc or PEI-CR16/pCAG-Luc with different N/P ratios (5, 10, 20 and 30) and containing 1  $\mu\text{g}$  pCAG-Luc was added to each well. The polyplexes were incubated with the cells for 36 h at  $37^{\circ}\text{C}$ . After removing the incubation medium, cells of each well were rinsed with PBS and frozen thawing in 200  $\mu\text{l}$  PBS at  $-80^{\circ}\text{C}$ . The luciferase activity in cells extracts was measured using a luciferase assay kit (Promega). Measurements were made in a single-well luminometer (Berthold Lumat LB 9507, Germany) for 10 s. The relative light units (RLUs) were normalized by determining the total protein of the extracts. PC-3 cells which express no FGF receptors on the cell membrane were used as negative control. Different concentrations of CR16 (0, 10, 50 and 100 nmol/L) were employed to investigate the free oligopeptide competitive inhibition effect by 3 h co-incubation before the procedure of gene transfer.

### In vivo gene transfer

Female BALB/C athymic nude mice (4~6 weeks of age) were used to in vivo gene transfer. Two million HepG2 or PC-3 cells (in 100  $\mu$ l saline) were locally injected into the dorsal site of the mice. When the size of tumor reached to 8 mm, the polyplexes of PEI/pDNA or PEI-CR16/pDNA containing 50  $\mu$ g pCAG-Luc with N/P ratio of 20 (in a volume of 100~150  $\mu$ l) were injected into the tumors. After 36 h, the mice were sacrificed and the tumors tissue samples were taken out and homogenized with 1 ml PBS and then subjected to three freeze-thaw cycles. The RLUs of the luciferase in the lysate were determined as the methods in in vitro experiments.

### Statistical analysis

Unless noted otherwise, results from in vitro experiments represented at least two independent experiments whereas in vivo experiments utilized six animals per group. All results are expressed as means $\pm$ SD. A mean with  $P < 0.05$  was considered statistically significant. The analysis method was one way ANOVA (SPSS, Version 12.0).

## RESULTS

### Synthesis and characterization of PEI-CR16

The polymer of PEI-CR16 was synthesized by linking CR16 to the primary amino groups of branch PEI (25 kDa). The molar ratio of PEI to CR16 was 1:0.75. The peaks in the  $\delta$  range of 3.2~3.5 were assigned to CR16 and the peaks in the  $\delta$  range of 2.5~3.2 were assigned to PEI in  $^1\text{H-NMR}$  assay. All of these demonstrated that CR16 was linked to PEI (Fig.1).

The PEI-CR16 was then determined by FT-IR. The absorbance peak of C=O at 1730  $\text{cm}^{-1}$  showed that CR16 had conjugated to PEI (Fig.2).

### Toxicity of PEI-CR16

The cytotoxicity of PEI-CR16 was investigated in HepG2 and PC-3 cells by MTT assay. Fig.3 shows that the cytotoxicity of PEI-CR16 was similar to that of PEI. When the concentration increased up to 10  $\mu$ g/ml or more, the viability of cells was less than 50% (Fig.3).




Fig.1  $^1\text{H}$  NMR analysis of PEI and PEI-CR16




Fig.2 FT-IR analysis of PEI and PEI-CR16

### Gel retardation and particle size assay of PEI-CR16

The plasmid DNA condensing ability of PEI-CR16 was detected by gel retardation assay. DNA was fully retarded at N/P ratio of 3 for PEI, and for PEI-CR16, it was at N/P ratio of 4 (Fig.4).

The particle size is shown in Fig.5. At N/P ratio of 10, the particle size was about 200 nm. At the same N/P ratio, the particle size of the polyplexes formed by PEI/pDNA was less than that of PEI-CR16 ( $P < 0.05$ ,  $n=10$ ).

### PEI-CR16 mediated gene transfer in vitro

Fig.6 shows the transgene efficiency of PEI and PEI-CR16 in HepG2 cells. It was twice that of PEI at N/P ratio of 10, and when the N/P ratio was 20, the efficiency was at least 6 times, but in PC-3 cells, it was lower than PEI.

The results of free CR16 competitive inhibition (Fig.7) indicated that free CR16 showed the inhibition





Fig.3 Toxicity of PEI and PEI-CR16 in (a) HepG2 cells and (b) PC-3 cells




Fig.4 Gel retardation assay of PEI and PEI-CR16




Fig.5 Particle size of the polyplexes complexed with pDNA by PEI and PEI-CR16





Fig.6 Transfection efficiency of PEI and PEI-CR16 in (a) HepG2 cells and (b) PC-3 cells

effect on the transgene activity of PEI-CR16 dependent on the concentration of free peptides, while no inhibition effect was observed on the transgene activity of uncoupled PEI.


**PEI-CR16 mediated gene transfer in vivo**

In the HepG2 tumor model, which highly expressed FGF receptors, the luciferase activity in the tumor tissues after intratumoral injection of the PEI-CR16/pCAG-luc complexes was significantly


higher than that in PEI/pCAG-luc ( $P=0.003, n=6$ ). On the contrary, in PC-3 tumor model which expressed FGF receptors weakly, no significant difference of luciferase activity was observed between the PEI-CR16 group and the PEI control group (Fig.8).

**DISCUSSION**

Since Boussif *et al.*(1995) developed PEI as the



**Fig.7** Transfection inhibition effect of free oligopeptide CR16 in HepG2 cells



**Fig.8** Transfection efficiency of PEI and PEI-CR16 in vivo with tumor model with HepG2 cells or PC-3 cells

hope for non-viral vector in gene delivery, PEI has become the golden criteria in the field of non-viral gene transfer vectors (Read *et al.*, 2005b). To make PEI more suitable for gene therapy, modifying PEI with ligands is one of the useful strategies, targeting specially to the receptors on cell membrane to improve the targeting ability of PEI. It is the most prospective future in gene therapy (Jeong *et al.*, 2005).

FGF receptors are highly expressed on most tumor cells and up-regulated in endothelial cells proliferating during angiogenesis and are attractive targets for cancer gene therapy (Chandler *et al.*, 1999). Though some papers reported FGF receptors targeting viral vectors with results coinciding with the re-targeting of the vectors and the improvement of gene expression (Chandler *et al.*, 2000), there is little research on the modification of PEI with FGF. In this study, the oligopeptides were designed from the same sequence of the FGF molecule's core fragment in order to diminish the steric hindrance of the whole FGF molecule.

PEI has abundant amine groups, so in the syn-

thesis system, the reaction was nearly complete between PEI and CR16. The molar ratio of CR16 to PEI in PEI-CR16 complexes could be obtained by referring to the theoretically calculated results (0.75:1).

The particle size of the polyplexes for gene delivery was about 200 nm and was affected by the type of polymer, size, modification of the carrier, and the protocol of complex formation. Considering the balance of factors the suitable diameter of polyplexes with more than 100 nm and less than 300 nm is suitable for the transfection (Munier *et al.*, 2005). Our results indicated the diameter of polyplexes prepared with PEI-CR16 and pDNA was suitable for transfection.

HepG2 cells and PC-3 cells were used to verify the gene transfer ability of PEI-CR16 and explore the role of the oligopeptide CR16. In our preliminary experiments, cell immunocytochemistry was used to screen the FGF receptors expression conditions in different cells including HepG2, PC-3 cells. The results showed that the positive expression of FGF receptors in HepG2 cells and the negative expression of FGF receptors in PC-3 cells, accorded with the results of Chandler *et al.* (1999) (data not showed). In vitro gene delivery experiments, we found that the most suitable N/P ratio was 10 for PEI and 20 for PEI-CR16. But even at N/P ratio of 10, the transfection efficiency of PEI-CR16 was higher than that of PEI. The difference between PEI-CR16 and PEI might have resulted from the relatively looser pDNA condensing ability and larger particle size. The relatively lower efficiency of PEI-CR16 on PC-3 cells was due to the fact that the linkage of CR16 had no receptor-mediated effect on PC-3 cells. But the effect of linkage on the steric hindrance of the peptide might decrease the efficiency. And, the free peptides CR16 added to the cell culture before the transfection showed efficient inhibition effect on the transgene ability of PEI-CR16, indicating that the combination of CR16 and FGF receptors mediated the enhanced transfection activity of PEI-CR16 in HepG2 cells. When PEI was modified with ligands, the pathway of polyplexes binding to cells will be receptor mediated replacement of simple static electricity process partly and thus enhances the efficiency (Grosse *et al.*, 2004). The mechanism of receptors-mediated gene transfer is very complex and not elucidated completely, including extracellular and intracellular pathways, but

according to some papers, the extracellular part may play a more important role (Wagner, 2004).

Preliminary research on gene delivery efficiency and the targeting ability of PEI-CR16 was investigated in vivo. As we expected, in tumor-bearing nude mice inoculated with HepG2 cells, the transgene expression of reporter gene in tumor tissues transfected by PEI-CR16 was higher than that of PEI mediated transfection. In the PC-3 tumor model, PEI-CR16 showed no enhanced transgene efficiency. But the amplitude of the enhanced transgene efficiency of PEI-CR16 was not so significant compared with the results of in vitro experiments. The reason may be imputed to the interaction of polyplexes with negative charges proteins like matrix proteins and the aggregation of tumors in the parenchyma (Ogris *et al.*, 1999). To decrease such interaction effect, some strategies like PEGylation may be helpful (Tang *et al.*, 2003).

In conclusion, a novel type of nonviral vectors based on PEI and modified with CR16 has been successfully developed which has higher transfection efficiency and FGF receptors retargeting ability. It will hopefully be directly used in gene therapy of cancer whether by local or systemic usage.

## References

- Boussif, O., Lezoualc'h, F., Zanta, M.A., Mergny, M.D., Scherman, D., Demeneix, B., Behr, J.P., 1995. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. *Proc. Natl. Acad. Sci. USA*, **92**(16):7297-7301. [doi:10.1073/pnas.92.16.7297]
- Chandler, L.A., Sosnowski, B.A., Greenlees, L., Aukerman, S.L., Baird, A., Pierce, G.F., 1999. Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines. *Int. J. Cancer*, **81**(3):451-458. [doi:10.1002/(SICI)1097-0215(19990505)81:3<451::AID-IJC20>3.3.CO;2-8]
- Chandler, L.A., Doukas, J., Gonzalez, A.M., Hoganson, D.K., Gu, D.L., Ma, C., Nesbit, M., Crombleholme, T.M., Herlyn, M., Sosnowski, B.A., *et al.*, 2000. FGF2-targeted adenovirus encoding platelet-derived growth factor-B enhances de novo tissue formation. *Mol. Ther.*, **2**(2): 153-160. [doi:10.1006/mthe.2000.0102]
- El-Aneed, A., 2004. An overview of current delivery systems in cancer gene therapy. *J. Control. Release*, **94**(1):1-14. [doi:10.1016/j.jconrel.2003.09.013]
- Grosse, S., Aron, Y., Honore, I., Thevenot, G., Danel, C., Roche, A.C., Monsigny, M., Fajac, I., 2004. Lactosylated polyethylenimine for gene transfer into airway epithelial cells: role of the sugar moiety in cell delivery and intracellular trafficking of the complexes. *J. Gene Med.*, **6**(3):345-356. [doi:10.1002/jgm.515]
- Jeong, J.H., Kim, S.H., Kim, S.W., Park, T.G., 2005. In vivo tumor targeting of ODN-PEG-folic acid/PEI polyelectrolyte complex micelles. *J. Biomater. Sci. Polym. Ed.*, **16**(11):1409-1419. [doi:10.1163/156856205774472335]
- Munier, S., Messai, I., Delair, T., Verrier, B., Ataman-Onal, Y., 2005. Cationic PLA nanoparticles for DNA delivery: comparison of three surface polycations for DNA binding, protection and transfection properties. *Colloids Surf. B Biointerfaces*, **43**(3-4):163-173. [doi:10.1016/j.colsurfb.2005.05.001]
- Neu, M., Fischer, D., Kissel, T., 2005. Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives. *J. Gene Med.*, **7**(8):992-1009. [doi:10.1002/jgm.773]
- Ogris, M., Brunner, S., Schuller, S., Kircheis, R., Wagner, E., 1999. PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. *Gene Ther.*, **6**(4):595-605. [doi:10.1038/sj.gt.3300900]
- Plotnikov, A.N., Hubbard, S.R., Schlessinger, J., Mohammadi, M., 2000. Crystal structures of two FGF-FGF receptors complexes reveal the determinants of ligand-receptor specificity. *Cell*, **101**(4):413-424. [doi:10.1016/S0092-8674(00)80851-X]
- Read, M.L., Logan, A., Seymour, L.W., 2005a. Barriers to gene delivery using synthetic vectors. *Adv. Genet.*, **53**: 19-46.
- Read, M.L., Singh, S., Ahmed, Z., Stevenson, M., Briggs, S.S., Oupicky, D., Barrett, L.B., Spice, R., Kendall, M., Berry, M., *et al.*, 2005b. A versatile reducible polycation-based system for efficient delivery of a broad range of nucleic acids. *Nucleic. Acids. Res.*, **33**(9):e86. [doi:10.1093/nar/gni085]
- Tang, G.P., Zeng, J.M., Gao, S.J., Ma, Y.X., Shi, L., Li, Y., Too, H.P., Wang, S., 2003. Polyethylene glycol modified polyethylenimine for improved CNS gene transfer: effects of PEGylation extent. *Biomaterials*, **24**(13):2351-2362. [doi:10.1016/S0142-9612(03)00029-2]
- Wagner, E., 2004. Strategies to improve DNA polyplexes for in vivo gene transfer: will "artificial viruses" be the answer? *Pharm. Res.*, **21**(1):8-14. [doi:10.1023/B:PHAM.0000012146.04068.56]